<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001244.v1.p1" parentStudy="phs001244.v1.p1" createDate="2016-11-14" modDate="2016-11-14">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Kwok-wai Lo</td><td>Chinese University of Hong Kong, Hong Kong, China</td></tr>
		<tr><td>Co-Investigator</td><td>Peter Hammerman</td><td>Dana-Farber Cancer Institute, Boston, MA, USA</td></tr>
		<tr><td>Co-Investigator</td><td>Yvonne Li</td><td>Dana-Farber Cancer Institute, Boston, MA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Nasopharynx Cancer Whole Exome Sequencing</StudyNameEntrez>
	<StudyNameReportPage>Nasopharynx Cancer Whole Exome Sequencing</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Cohort</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Nasopharyngeal carcinoma (NPC) is an aggressive head and neck cancer characterized by Epstein-Barr virus (EBV) infection and dense lymphocyte infiltration. The scarcity of NPC genomic data hinders the understanding of NPC biology, disease progression, and rational therapy design. Here, we performed whole-exome sequencing (WES) on 111 micro-dissected EBV-positive NPCs, with 15 cases subjected to further whole-genome sequencing (WGS), to determine its mutational landscape. We identified enrichment for genomic aberrations of multiple negative regulators of the NF-kB pathway in a total of 41% of cases including CYLD, TRAF3, NFKBIA and NLRC5. Functional analysis confirmed novel inactivating CYLD mutations as drivers for NPC cell growth. The EBV oncoprotein latent member protein 1 (LMP1) functions to constitutively activate NF-kB signaling, and we observed mutual exclusivity among somatic NF-kB pathway aberrations and LMP1-overexpression, suggesting that NF-kB activation is selected for by both somatic and viral events during NPC pathogenesis.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Subjects were selected on the basis of biopsy proven nasopharynx cancer and restricted to treatment naive individuals. In cases where multiple tumors were available these were included.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Nasopharyngeal Neoplasms"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Kwok-wai Lo</AttName>
			<Institution>Chinese University of Hong Kong, Hong Kong, China</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Peter Hammerman</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Yvonne Li</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston, MA, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>This study was conducted to describe the genomic landscape of nasopharynx cancer.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-CA-NPU-MDS" longName="Disease-Specific (Cancer, NPU, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001244.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001244.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001244.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Cancer, NPU, MDS)</ConsentName>
        <ConsentAbbrev>DS-CA-NPU-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer.
Use of the data is limited to not-for-profit organizations.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
